Clinical and biologic implications of recurrent genomic aberrations in myeloma. - Wikidata - wikimedia - TriplyDB

Clinical and biologic implications of recurrent genomic aberrations in myeloma.

Clinical and biologic implications of recurrent genomic aberrations in myeloma.

http://www.wikidata.org/entity/Q44776402

about

Deficient spindle assembly checkpoint in multiple myeloma Prognostic significance of copy-number alterations in multiple myeloma Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms.Clinical and biological significance of RAS mutations in multiple myeloma.Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma Identification of ID-1 as a potential target gene of MMSET in multiple myeloma Advances in understanding prognosis in myeloma.Impact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03.Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project.Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group.Plasma cell leukemia.How I treat plasma cell leukemia.Identification of novel pathogenic copy number aberrations in multiple myeloma: the Malaysian context Novel therapies in multiple myeloma for newly diagnosed nontransplant candidates Anticancer Role of PPARgamma Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes.Identification and expression of MMSA-8, and its clinical significance in multiple myeloma.Clinical implications of c-maf expression in plasma cells from patients with multiple myeloma.p53 abnormalities and potential therapeutic targeting in multiple myeloma.Expression of CD99 in Multiple Myeloma: A Clinicopathologic and Immunohistochemical Study of 170 Cases.Implications of heterogeneity in multiple myeloma.Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation.The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy.A critical role for the NFkB pathway in multiple myeloma.Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival.International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma.Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease.SAMSN1 is a tumor suppressor gene in multiple myeloma.The molecular classification of multiple myeloma Arsenic trioxide-mediated growth inhibition of myeloma cells is associated with an extrinsic or intrinsic signaling pathway through activation of TRAIL or TRAIL receptor 2.Predictive value of post-transplant bone marrow plasma cell percent in multiple myeloma patients undergone autologous transplantation.Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients.Dilemmas in treating smoldering multiple myeloma.Prognostic value and efficacy evaluation of novel drugs for cytogenetic aberrations in multiple myeloma: a meta-analysis.Retrospective analysis of genetic abnormalities and survival in 131 patients with multiple myeloma.

P2860

Q21560908-B26F82C0-A7CC-429E-BD16-BCD74CBECD15 Q24643402-71054B66-9087-486E-A3CC-308FCAB21AA2 Q24647620-E71DB3DF-F11B-42A3-820A-2C8E6C238300 Q24670250-E645AC90-CD74-47A0-B690-E1F915C01478 Q27654979-06F57CC8-DB05-45A2-9C97-45E78BA2B97E Q27692033-8387E558-46AA-45A5-B17C-1F0395498A5C Q27851434-9B2AC9E1-5955-4F8D-A440-14A8C05701A6 Q28074490-1D54962D-C041-4831-879C-3B5F9302E950 Q28268453-8A109F60-A20F-4351-AFE7-467EAC01C022 Q30244061-6EF6BF23-DDE6-4F42-B633-E07246C9DFF3 Q30424188-F0B15DF1-949C-4072-B2FC-2CC26FF378B3 Q30571858-A586AE0B-BF28-4475-BA1C-BB359CDB9A42 Q31154933-3758D59F-25BA-4CF0-AF9F-91F11F0B3404 Q33393995-6D16B5D8-8268-49F7-A492-37DCAD0D5548 Q33402555-3DB14929-B974-4249-8ED1-703058F30590 Q33614522-AEBB1B74-AFA5-4D78-B1BC-E6595DC699C8 Q33639796-1DD5D81B-9B44-4E07-90FE-A7B1223C8626 Q33692555-36CBB9E7-F862-4CB1-9BA3-A84A38D598B9 Q33721123-7B1030EC-A516-48C6-A43A-F68994739734 Q33733709-C772B4E4-0244-4060-B931-5BD01F41BB2E Q33852683-989EA342-A568-4E94-A2AD-BE0DCEC5EF6A Q33864974-DFA45CB7-57F6-452D-B5A9-83FE2E4D18BA Q33914824-1CD83FA9-4D78-4BE4-AC2E-8527526693AB Q33942495-26D945BB-7492-4BA2-AE37-036DD3948E0D Q33952805-FEEFF886-5A2C-45BF-8C49-D27F11036FCD Q33952861-4D424F1B-0AC1-4D8B-A77F-F059FF98C90C Q33973877-BD8CAB41-2D61-430A-A080-BFFC38C77033 Q34165181-E6299705-8559-4F07-A669-3930C6779E5D Q34223730-BF30E3BC-2343-42AD-835F-03C876975B23 Q34241661-7429EC96-E88B-468F-91AD-B113ED4FE61D Q34296442-ACB372A5-EE1E-4F72-BFA7-C86065C43DD3 Q34316559-5161B3B1-4F52-4255-B17D-E39E2A73DDE5 Q34347229-7858E601-ADE7-45EE-8DBE-0870A7284EC5 Q34530992-D5DA4CB7-DE77-414F-AE47-9CF5B113ABD1 Q34616652-C2066A0D-FB7A-4F02-8BD8-93E302580246 Q34665449-E7FE9BBC-D8F2-46EC-ADC2-77085775BB53 Q34671809-3CA3229A-37BB-469C-856C-552C6D53C868 Q34716500-FDF23767-C869-4947-AAF2-A0B954AADC28 Q34769841-8099345F-1E2B-4059-AC3F-793E8CD3C127 Q34993904-4E103CD6-1FE6-47E8-929A-FF9A5FBAC610

P2860

Clinical and biologic implications of recurrent genomic aberrations in myeloma.

http://www.wikidata.org/entity/Q44776402

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

Clinical and biologic implications of recurrent genomic aberrations in myeloma.

@en

Clinical and biologic implications of recurrent genomic aberrations in myeloma.

@nl

type

label

Clinical and biologic implications of recurrent genomic aberrations in myeloma.

@en

Clinical and biologic implications of recurrent genomic aberrations in myeloma.

@nl

prefLabel

Clinical and biologic implications of recurrent genomic aberrations in myeloma.

@en

Clinical and biologic implications of recurrent genomic aberrations in myeloma.

@nl

P1433

Q44776402-B5300832-F886-495A-AFB8-92EA0060B5F0

P1476

Q44776402-8ABB4671-06DB-4A02-881D-E458944F79B1

P2093

Q44776402-484047B5-A644-472A-B549-BD36DD4120EC

Q44776402-74240981-4411-4FEB-986D-DB3E3397D6EC

Q44776402-7CFC7718-8016-4489-B1BA-CE4222C9A843

Q44776402-7E251379-12A8-483B-8457-580FA7C68822

Q44776402-8522EF94-10FB-47FC-A914-C469D4D94AE6

Q44776402-A38FE405-C809-46B7-8D1C-DABEBE48B358

Q44776402-C645D1BF-D70F-462F-B6E3-77740A9AA261

Q44776402-CA4BECAB-1AF0-4193-9746-58643AB197E2

Q44776402-DC4ECA25-0514-4E71-A470-B04288327097

Q44776402-DFD71019-E862-4C9F-A4EA-2A62805D3309

P304

Q44776402-1C77E74B-BCED-4480-85E1-520A1C41C960

P31

Q44776402-C207D721-8426-4B36-AFFC-8CE299B285A7

P356

Q44776402-6CC1BF17-C310-4C93-847D-2C3B7ABA432F

P407

Q44776402-30C229EA-619E-41FC-B5A9-11076E91CB23

P433

Q44776402-129DE80B-88CE-4016-9807-874A0CB5FE36

P478

Q44776402-8243EE29-2B64-47C9-9CA5-28808CC3B648

P50

Q44776402-22059866-D67C-4D86-B953-C86177DBAAEC

Q44776402-A0835C9F-A497-43D0-ADB5-726E6C76D51D

Q44776402-A1582896-03A6-401A-9B38-BC47E3EC15CD

P577

Q44776402-D255375F-B161-430A-900C-BE9453D4FBBE

P5875

Q44776402-10983D27-B30F-4ECC-8A69-837BF51878AF

P698

Q44776402-141CA404-032E-4255-A7BF-F12253A431FB

P356

BLOOD-2002-10-3017

P1433

P1476

Clinical and biologic implications of recurrent genomic aberrations in myeloma.

@en

P2093

Brian Van Ness

http://www.w3.org/2001/XMLSchema#string

David Harrington

http://www.w3.org/2001/XMLSchema#string

Emily Blood

http://www.w3.org/2001/XMLSchema#string

Gordon W Dewald

http://www.w3.org/2001/XMLSchema#string

Kimberly J Henderson

http://www.w3.org/2001/XMLSchema#string

Martin M Oken

http://www.w3.org/2001/XMLSchema#string

Montserrat Rue

http://www.w3.org/2001/XMLSchema#string

Philip R Greipp

http://www.w3.org/2001/XMLSchema#string

Richard J Bailey

http://www.w3.org/2001/XMLSchema#string

Scott A Van Wier

http://www.w3.org/2001/XMLSchema#string

P304

4569-4575

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2002-10-3017

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

101

http://www.w3.org/2001/XMLSchema#string

P50

P577

2003-02-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10910416

http://www.w3.org/2001/XMLSchema#string

P698

12576322

http://www.w3.org/2001/XMLSchema#string